EFFECT OF A BRADYCARDIC AGENT ON THE ISOLATED BLOOD-PERFUSED CANINE HEART

被引:31
作者
SCHIPKE, JD
HARASAWA, Y
SUGIURA, S
ALEXANDER, J
BURKHOFF, D
机构
[1] Dept. of Experimental Surgery, Universität Düsseldorf, Düsseldorf, D-4000
[2] Dept. of Biomedical Engineering, School of Medicine, The Johns Hopkins University, Baltimore, MD
关键词
CANINE HEART; CARDIAC OUTPUT; BRADYCARDIC AGENT; UL-FS; 49; CORONARY RESISTANCE; MYOCARDIAL OXYGEN CONSUMPTION; LEFT VENTRICULAR CONTRACTILITY;
D O I
10.1007/BF03029773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bradycardic agents could limit the consequences of myocardial ischemia via two mechanisms: by decreasing myocardial oxygen demand (MVO2) and by increasing diastolic coronary blood flow (CBF). We investigated whether the benzazepinon UL-FS 49 affects only sinus node cells or also smooth muscle and/or myocardial cells. To avoid confounding interactions with the periphery, we performed experiments on 11 isolated, blood-perfused canine hearts. Injection of UL-FS 49 (1 mg/kg i.c.) significantly reduced heart rate (HR) from 104 +/- 7 to 93 +/- 7 min-1 (mean +/- SEM) and increased stroke volume (n = 6: 9.8 +/- 1.1 vs. 13.2 +/- 1.6 ml), so that cardiac output remained unchanged (n = 6: 1.1 +/- 0.1 vs. 1.2 +/- 0.1 1/min). The contractile state, assessed by isovolumic peak systolic pressure, was unaltered by UL-FS 49 (n = 5: 72 +/- 6 vs. 72 +/- 6 mmHg). At a constant coronary arterial pressure (CAP) of 80 mmHg, mean CBF was slightly decreased (102 +/- 11 vs. 97 +/- 10 ml/[min.100 g]) by UL-FS 49, such that mean coronary resistance remained unchanged (0.9 +/- 0.1 vs 1.0 +/- 0.1 mmHg . min . 100 g/ml). The slight decreases in arteriovenous oxygen content difference (n = 6: 6.6 +/- 0.7 vs. 6.5 +/- 0.7 ml/100 ml) and in CBF lead to a calculated, significant decrease in MVO2 (n = 6: 6.9 +/- 0.5 vs. 6.0 +/- 0.4 ml . 100 g/min). In conclusion, UL-FS 49 at the dose used decreases MVO2 by reducing HR in isolated canine hearts. In the absence of negative inotropic and vasodilating effects, cardiac output is maintained via increased stroke volume, and CAP will likely be preserved in situ. Thus, this specific bradycardic agent could be useful in treating ischemic myocardial disease.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 40 条
[1]  
Braunwald E., Control of myocardial oxygen consumption. Physiological and clinical considerations, Am J Cardiol, 27, pp. 416-432, (1971)
[2]  
Gillam P., Use of propranolol in angina pectoris, Br Med J, 2, pp. 337-339, (1965)
[3]  
Dagenais G.R., Pitt B., Ross R.S., Exercise tolerance in patients with angina pectoris. Daily variation and effects of erythrityl tetranitrate, propranolol and alprenolol, Am J Cardiol, 28, pp. 10-16, (1971)
[4]  
Henry P.D., Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem, Am J Cardiol, 46, pp. 1047-1058, (1980)
[5]  
Josephson M.A., Singh B.N., Use of calcium antagonists in ventricular dysfunction, The American Journal of Cardiology, 55, pp. 81B-85B, (1985)
[6]  
Vatner S.F., Hintze T.H., Effects of a calcium-channel antagonist on large and small coronary vessels in conscious dogs, Circulation, 66, pp. 579-587, (1982)
[7]  
Nayler W., Dillon J.S., Daly M.J., Cellular sites of action of calcium antagonists and β-adrenoceptor blockers, Calcium antagonists and cardiovascular disease, pp. 181-192, (1984)
[8]  
Heusch G., Deussen A., Schipke J., Et al., α<sub>1</sub> and α<sub>2</sub>-adrenoceptor-mediated vasoconstriction of large and small canine coronary arteries in vivo, J Cardiovasc Pharmacol, 6, pp. 961-968, (1984)
[9]  
Schamhardt H.C., Verdouw P.D., Saxena P.R., Improvement of perfusion and function of ischemic porcine myocardium after reduction of heart rate by alinidine, J Cardiovasc Pharmacol, 3, pp. 728-738, (1981)
[10]  
Dammgen J.W., Lamping K.A., Gross G.J., Actions of two new bradycardic agents, Journal of Cardiovascular Pharmacology, 7, pp. 71-79, (1985)